Sharp Brains: Brain Fitness and Cognitive Health News

Neuroplasticity, Brain Fitness and Cognitive Health News


Study: Psychedelics can promote neural plasticity in the prefrontal cortex and expand pathways for mental health

– Cred­it: Cell Reports 2018 23, 3170–3182DOI: (10.1016/j.celrep.2018.05.022). Copy­right © 2018 The Authors


Psy­che­delics in Neu­rol­o­gy: Poten­tial for Improv­ing Neu­ro­plas­tic­i­ty (Neu­rol­o­gy­Times):

Back in the 1950s, research was prov­ing that psy­che­del­ic agents could be effec­tive in the treat­ment of var­i­ous neu­ropsy­chi­atric dis­or­ders. Unfor­tu­nate­ly, just as sci­ence was explor­ing their ben­e­fi­cial effects, the coun­ter­cul­ture was explor­ing and embrac­ing their effects. Slow­ly but sure­ly, psy­che­delics were asso­ci­at­ed with rebel­lious youth and the tumul­tuous anti-war move­ment. As a result, the gov­ern­ment shut down most of the research.

The 1990s saw renewed inter­est in psy­che­del­ic com­pounds as a means to address neu­ropsy­chi­atric dis­or­ders. Research explored the ben­e­fits of MDMA and ket­a­mine to treat mood dis­or­ders and post­trau­mat­ic stress dis­or­der. Now, a new study sheds even more light on the promise these agents might pro­vide.

Neu­rol­o­gy Times invit­ed cor­re­spond­ing author David E Olson, PhD, to dis­cuss the study, “Psy­che­delics Pro­mote Struc­tur­al and Func­tion­al Neur­al Plas­tic­i­ty,” which appeared in the June issue of Cell Reports…

NT: What should clin­i­cians take away from this research? What does this mean for the field?

Dr Olson: I’m hope­ful that mod­ern research on ket­a­mine and psy­che­delics will lead to new and more effec­tive strate­gies for treat­ing mood and anx­i­ety dis­or­ders that involve pro­mot­ing neur­al plas­tic­i­ty in the pre­frontal cor­tex. We have to think of depres­sion and relat­ed dis­eases as dis­or­ders of neur­al cir­cuits rather than “chem­i­cal imbal­ances.” Plas­tic­i­ty-pro­mot­ing com­pounds are one pos­si­ble method for repair­ing the cir­cuits that are dam­aged in dis­eases like depres­sion and post­trau­mat­ic stress dis­or­der.”

The Study:

Psy­che­delics Pro­mote Struc­tur­al and Func­tion­al Neur­al Plas­tic­i­ty (Cell Reports). From the abstract:

  • Atro­phy of neu­rons in the pre­frontal cor­tex (PFC) plays a key role in the patho­phys­i­ol­o­gy of depres­sion and relat­ed dis­or­ders. The abil­i­ty to pro­mote both struc­tur­al and func­tion­al plas­tic­i­ty in the PFC has been hypoth­e­sized to under­lie the fast-act­ing anti­de­pres­sant prop­er­ties of the dis­so­cia­tive anes­thet­ic ket­a­mine. Here, we report that, like ket­a­mine, sero­ton­er­gic psy­che­delics are capa­ble of robust­ly increas­ing neu­ri­to­ge­n­e­sis and/or spin­o­gen­e­sis both in vit­ro and in vivo. These changes in neu­ronal struc­ture are accom­pa­nied by increased synapse num­ber and func­tion, as mea­sured by flu­o­res­cence microscopy and elec­tro­phys­i­ol­o­gy. The struc­tur­al changes induced by psy­che­delics appear to result from stim­u­la­tion of the TrkB, mTOR, and 5‑HT2A sig­nal­ing path­ways and could pos­si­bly explain the clin­i­cal effec­tive­ness of these com­pounds. Our results under­score the ther­a­peu­tic poten­tial of psy­che­delics and, impor­tant­ly, iden­ti­fy sev­er­al lead scaf­folds for med­i­c­i­nal chem­istry efforts focused on devel­op­ing plas­tic­i­ty-pro­mot­ing com­pounds as safe, effec­tive, and fast-act­ing treat­ments for depres­sion and relat­ed dis­or­ders.

The Study in Context:

Leave a Reply...

Loading Facebook Comments ...

Leave a Reply

Categories: Cognitive Neuroscience, Health & Wellness, Peak Performance, Technology

Tags: , , , , , , , , , , , , , , , , , , , ,

Search in our archives

About SharpBrains

As seen in The New York Times, The Wall Street Journal, BBC News, CNN, Reuters,  SharpBrains is an independent market research firm tracking how brain science can improve our health and our lives.

Follow us and Engage via…

RSS Feed

Watch All Recordings Now (40+ Speakers, 12+ Hours)